The regulatory T cells (Tregs) can be attracted by CCL22 into the tumor microenvironment, to reduce anti-cancer immunity [18], which are widely expressed in many cancers, including glioma, gastric cancer, and breast cancer [19–21]. This evidence concerns the gene CCL22 and central nervous system cancer.